All trades / MASS
MASS
908 Devices Inc.
247Open-market trades
+0.71%Avg 90d after buys
+5.91%Avg 90d after sales
−15.4%Avg 180d after buys
Price and insider prints
MASS adjusted close▲ buy▼ sale
Trades
| Date | Form 4 | Ticker | Insider | Title | Side | Shares | Value | 90d | 180d |
|---|---|---|---|---|---|---|---|---|---|
| 9/17/2026 | Form 4 | MASS 10b5-1 | Kenneweg John | SVP, Sales & Product Marketing | SELL | 5,257 | $53.7K | +12.9%hist | +33.1%hist |
| 9/16/2026 | Form 4 | MASS 10b5-1 | Kenneweg John | SVP, Sales & Product Marketing | SELL | 21,399 | $216.3K | +12.9%hist | +33.1%hist |
| 9/15/2026 | Form 4 | MASS 10b5-1 | Kenneweg John | SVP, Sales & Product Marketing | SELL | 1,000 | $10.0K | +12.9%hist | +33.1%hist |
| 9/2/2026 | Form 4 | MASS 10b5-1 | Brown Christopher D.Dr. Brown has served as Vice President of R&D Analytics at Repligen Corporation (NASDAQ: RGEN), or Repligen, following Repligen’s acquisition of the bioprocessing analytics portfolio of 908 Devices. From March 2023 through March 2025, he was our Chief Product Officer, and from February 2012 to March 2023, he was our Chief Technology Officer and Vice President of Research and Development. Prior to co-founding 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ: AAPL), leading investigations in future-gen health-technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific, Inc. (NYSE: TMO) and from 2005 until 2010 he was Senior Director… | Director | SELL | 30,000 | $317.4K | +5.44%hist | +18.6%hist |
| 8/25/2026 | Form 4 | MASS 10b5-1 | Griffith Joseph H. IV | Chief Financial Officer | SELL | 11,459 | $125.5K | +2.86%hist | +15.6%hist |
| 8/21/2026 | Form 4 | MASS | AWM Investment Company, Inc. | 10% owner | SELL | 41,578 | $441.2K | +11.6%hist | +19.0%hist |
| 8/20/2026 | Form 4 | MASS | AWM Investment Company, Inc. | 10% owner | SELL | 8,422 | $88.6K | +11.6%hist | +19.0%hist |
| 8/17/2026 | Form 4 | MASS 10b5-1 | Knopp Kevin J. | President and CEO | SELL | 20,000 | $207.0K | +9.69%hist | +23.4%hist |
| 8/13/2026 | Form 4 | MASS 10b5-1 | Knopp Kevin J. | President and CEO | SELL | 7,622 | $76.7K | +9.69%hist | +23.4%hist |
| 8/12/2026 | Form 4 | MASS 10b5-1 | Knopp Kevin J. | President and CEO | SELL | 2,747 | $27.7K | +9.69%hist | +23.4%hist |
| 8/11/2026 | Form 4 | MASS 10b5-1 | Knopp Kevin J. | President and CEO | SELL | 30,170 | $306.5K | +9.69%hist | +23.4%hist |
| 8/11/2026 | Form 4 | MASS 10b5-1 | Knopp Kevin J. | President and CEO | SELL | 115,748 | $1.14M | +9.69%hist | +23.4%hist |
| 8/11/2026 | Form 4 | MASS 10b5-1 | Brown Christopher D.Dr. Brown has served as Vice President of R&D Analytics at Repligen Corporation (NASDAQ: RGEN), or Repligen, following Repligen’s acquisition of the bioprocessing analytics portfolio of 908 Devices. From March 2023 through March 2025, he was our Chief Product Officer, and from February 2012 to March 2023, he was our Chief Technology Officer and Vice President of Research and Development. Prior to co-founding 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ: AAPL), leading investigations in future-gen health-technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific, Inc. (NYSE: TMO) and from 2005 until 2010 he was Senior Director… | Director | SELL | 8,358 | $77.1K | +5.44%hist | +18.6%hist |
| 8/10/2026 | Form 4 | MASS 10b5-1 | Knopp Kevin J. | President and CEO | SELL | 348 | $3.2K | +9.69%hist | +23.4%hist |
| 8/10/2026 | Form 4 | MASS 10b5-1 | Brown Christopher D.Dr. Brown has served as Vice President of R&D Analytics at Repligen Corporation (NASDAQ: RGEN), or Repligen, following Repligen’s acquisition of the bioprocessing analytics portfolio of 908 Devices. From March 2023 through March 2025, he was our Chief Product Officer, and from February 2012 to March 2023, he was our Chief Technology Officer and Vice President of Research and Development. Prior to co-founding 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ: AAPL), leading investigations in future-gen health-technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific, Inc. (NYSE: TMO) and from 2005 until 2010 he was Senior Director… | Director | SELL | 9,442 | $85.3K | +5.44%hist | +18.6%hist |
| 8/5/2026 | Form 4 | MASS 10b5-1 | Brown Christopher D.Dr. Brown has served as Vice President of R&D Analytics at Repligen Corporation (NASDAQ: RGEN), or Repligen, following Repligen’s acquisition of the bioprocessing analytics portfolio of 908 Devices. From March 2023 through March 2025, he was our Chief Product Officer, and from February 2012 to March 2023, he was our Chief Technology Officer and Vice President of Research and Development. Prior to co-founding 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ: AAPL), leading investigations in future-gen health-technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific, Inc. (NYSE: TMO) and from 2005 until 2010 he was Senior Director… | Director | SELL | 20,000 | $169.8K | +5.44%hist | +18.6%hist |
| 8/4/2026 | Form 4 | MASS | AWM Investment Company, Inc. | 10% owner | SELL | 50,000 | $417.8K | +11.6%hist | +19.0%hist |
| 7/2/2026 | Form 4 | MASS 10b5-1 | Knopp Kevin J. | President and CEO | SELL | 222 | $2.0K | +9.69%hist | +23.4%hist |
| 7/2/2026 | Form 4 | MASS 10b5-1 | Brown Christopher D.Dr. Brown has served as Vice President of R&D Analytics at Repligen Corporation (NASDAQ: RGEN), or Repligen, following Repligen’s acquisition of the bioprocessing analytics portfolio of 908 Devices. From March 2023 through March 2025, he was our Chief Product Officer, and from February 2012 to March 2023, he was our Chief Technology Officer and Vice President of Research and Development. Prior to co-founding 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ: AAPL), leading investigations in future-gen health-technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific, Inc. (NYSE: TMO) and from 2005 until 2010 he was Senior Director… | Director | SELL | 2,200 | $19.8K | +5.44%hist | +18.6%hist |
| 6/30/2026 | Form 4 | MASS 10b5-1 | Brown Christopher D.Dr. Brown has served as Vice President of R&D Analytics at Repligen Corporation (NASDAQ: RGEN), or Repligen, following Repligen’s acquisition of the bioprocessing analytics portfolio of 908 Devices. From March 2023 through March 2025, he was our Chief Product Officer, and from February 2012 to March 2023, he was our Chief Technology Officer and Vice President of Research and Development. Prior to co-founding 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ: AAPL), leading investigations in future-gen health-technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific, Inc. (NYSE: TMO) and from 2005 until 2010 he was Senior Director… | Director | SELL | 20,000 | $176.8K | +5.44%hist | +18.6%hist |
| 6/26/2026 | Form 4 | MASS 10b5-1 | Knopp Kevin J. | President and CEO | SELL | 2,798 | $25.4K | +9.69%hist | +23.4%hist |
| 6/25/2026 | Form 4 | MASS 10b5-1 | Knopp Kevin J. | President and CEO | SELL | 16,388 | $149.1K | +9.69%hist | +23.4%hist |
| 6/24/2026 | Form 4 | MASS 10b5-1 | Knopp Kevin J. | President and CEO | SELL | 40,535 | $370.5K | +9.69%hist | +23.4%hist |
| 6/23/2026 | Form 4 | MASS 10b5-1 | Knopp Kevin J. | President and CEO | SELL | 3,422 | $31.0K | +9.69%hist | +23.4%hist |
| 6/23/2026 | Form 4 | MASS 10b5-1 | Brown Christopher D.Dr. Brown has served as Vice President of R&D Analytics at Repligen Corporation (NASDAQ: RGEN), or Repligen, following Repligen’s acquisition of the bioprocessing analytics portfolio of 908 Devices. From March 2023 through March 2025, he was our Chief Product Officer, and from February 2012 to March 2023, he was our Chief Technology Officer and Vice President of Research and Development. Prior to co-founding 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ: AAPL), leading investigations in future-gen health-technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific, Inc. (NYSE: TMO) and from 2005 until 2010 he was Senior Director… | Director | SELL | 9,900 | $89.5K | +5.44%hist | +18.6%hist |
| 6/23/2026 | Form 4 | MASS | AWM Investment Company, Inc. | 10% owner | SELL | 3,050 | $27.4K | +11.6%hist | +19.0%hist |
| 6/22/2026 | Form 4 | MASS | AWM Investment Company, Inc. | 10% owner | SELL | 4,668 | $42.0K | +11.6%hist | +19.0%hist |
| 6/4/2026 | Form 4 | MASS | AWM Investment Company, Inc. | 10% owner | SELL | 39,782 | $356.8K | −17.1% | +19.0%hist |
| 6/4/2026 | Form 4 | MASS 10b5-1 | Brown Christopher D.Dr. Brown has served as Vice President of R&D Analytics at Repligen Corporation (NASDAQ: RGEN), or Repligen, following Repligen’s acquisition of the bioprocessing analytics portfolio of 908 Devices. From March 2023 through March 2025, he was our Chief Product Officer, and from February 2012 to March 2023, he was our Chief Technology Officer and Vice President of Research and Development. Prior to co-founding 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ: AAPL), leading investigations in future-gen health-technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific, Inc. (NYSE: TMO) and from 2005 until 2010 he was Senior Director… | Director | SELL | 100 | $900.00 | −17.1% | +18.6%hist |
| 6/3/2026 | Form 4 | MASS 10b5-1 | Brown Christopher D.Dr. Brown has served as Vice President of R&D Analytics at Repligen Corporation (NASDAQ: RGEN), or Repligen, following Repligen’s acquisition of the bioprocessing analytics portfolio of 908 Devices. From March 2023 through March 2025, he was our Chief Product Officer, and from February 2012 to March 2023, he was our Chief Technology Officer and Vice President of Research and Development. Prior to co-founding 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ: AAPL), leading investigations in future-gen health-technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific, Inc. (NYSE: TMO) and from 2005 until 2010 he was Senior Director… | Director | SELL | 20,000 | $174.6K | −23.0% | +18.6%hist |
| 6/2/2026 | Form 4 | MASS | AWM Investment Company, Inc. | 10% owner | SELL | 2,500 | $22.4K | −20.6% | +19.0%hist |
| 5/28/2026 | Form 4 | MASS 10b5-1 | Brown Christopher D.Dr. Brown has served as Vice President of R&D Analytics at Repligen Corporation (NASDAQ: RGEN), or Repligen, following Repligen’s acquisition of the bioprocessing analytics portfolio of 908 Devices. From March 2023 through March 2025, he was our Chief Product Officer, and from February 2012 to March 2023, he was our Chief Technology Officer and Vice President of Research and Development. Prior to co-founding 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ: AAPL), leading investigations in future-gen health-technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific, Inc. (NYSE: TMO) and from 2005 until 2010 he was Senior Director… | Director | SELL | 30,000 | $270.0K | −16.1% | +18.6%hist |
| 5/28/2026 | Form 4 | MASS 10b5-1 | Griffith Joseph H. IV | Chief Financial Officer | SELL | 6,940 | $62.7K | −16.1% | +15.6%hist |
| 5/28/2026 | Form 4 | MASS | AWM Investment Company, Inc. | 10% owner | SELL | 170,442 | $1.48M | −16.1% | +19.0%hist |
| 5/27/2026 | Form 4 | MASS | AWM Investment Company, Inc. | 10% owner | SELL | 1,500 | $12.4K | −34.8% | +19.0%hist |
| 5/27/2026 | Form 4 | MASS | AWM Investment Company, Inc. | 10% owner | SELL | 15,000 | $123.8K | −34.8% | +19.0%hist |
| 5/11/2026 | Form 4 | MASS | AWM Investment Company, Inc. | 10% owner | SELL | 5,000 | $41.3K | −11.0% | +19.0%hist |
| 5/8/2026 | Form 4 | MASS | Kenneweg John | SVP, Sales & Product Marketing | SELL | 18,255 | $148.0K | −1.59% | +33.1%hist |
| 5/8/2026 | Form 4 | MASS | AWM Investment Company, Inc. | 10% owner | SELL | 3,025 | $24.8K | −1.59% | +19.0%hist |
| 5/7/2026 | Form 4 | MASS | AWM Investment Company, Inc. | 10% owner | SELL | 12,819 | $105.1K | −4.08% | +19.0%hist |
| 5/6/2026 | Form 4 | MASS | AWM Investment Company, Inc. | 10% owner | SELL | 57,365 | $462.4K | −4.84% | +19.0%hist |
| 5/6/2026 | Form 4 | MASS | AWM Investment Company, Inc. | 10% owner | SELL | 5,000 | $40.0K | −4.84% | +19.0%hist |
| 5/6/2026 | Form 4 | MASS 10b5-1 | Brown Christopher D.Dr. Brown has served as Vice President of R&D Analytics at Repligen Corporation (NASDAQ: RGEN), or Repligen, following Repligen’s acquisition of the bioprocessing analytics portfolio of 908 Devices. From March 2023 through March 2025, he was our Chief Product Officer, and from February 2012 to March 2023, he was our Chief Technology Officer and Vice President of Research and Development. Prior to co-founding 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ: AAPL), leading investigations in future-gen health-technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific, Inc. (NYSE: TMO) and from 2005 until 2010 he was Senior Director… | Director | SELL | 20,000 | $144.6K | −4.84% | +18.6%hist |
| 5/1/2026 | Form 4 | MASS | Kenneweg John | SVP, Sales & Product Marketing | SELL | 7,787 | $53.2K | −12.2% | +33.1%hist |
| 4/10/2026 | Form 4 | MASS 10b5-1 | Brown Christopher D.Dr. Brown has served as Vice President of R&D Analytics at Repligen Corporation (NASDAQ: RGEN), or Repligen, following Repligen’s acquisition of the bioprocessing analytics portfolio of 908 Devices. From March 2023 through March 2025, he was our Chief Product Officer, and from February 2012 to March 2023, he was our Chief Technology Officer and Vice President of Research and Development. Prior to co-founding 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ: AAPL), leading investigations in future-gen health-technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific, Inc. (NYSE: TMO) and from 2005 until 2010 he was Senior Director… | Director | SELL | 17,578 | $124.3K | −13.9% | +18.6%hist |
| 4/10/2026 | Form 4 | MASS 10b5-1 | McCallion Kevin J. | SVP, Products and Production | SELL | 2,693 | $18.9K | −13.9% | −61.4%hist |
| 4/9/2026 | Form 4 | MASS 10b5-1 | Brown Christopher D.Dr. Brown has served as Vice President of R&D Analytics at Repligen Corporation (NASDAQ: RGEN), or Repligen, following Repligen’s acquisition of the bioprocessing analytics portfolio of 908 Devices. From March 2023 through March 2025, he was our Chief Product Officer, and from February 2012 to March 2023, he was our Chief Technology Officer and Vice President of Research and Development. Prior to co-founding 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ: AAPL), leading investigations in future-gen health-technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific, Inc. (NYSE: TMO) and from 2005 until 2010 he was Senior Director… | Director | SELL | 7,392 | $52.0K | −13.2% | +18.6%hist |
| 4/9/2026 | Form 4 | MASS 10b5-1 | McCallion Kevin J. | SVP, Products and Production | SELL | 5,420 | $38.1K | −13.2% | −61.4%hist |
| 4/8/2026 | Form 4 | MASS 10b5-1 | Brown Christopher D.Dr. Brown has served as Vice President of R&D Analytics at Repligen Corporation (NASDAQ: RGEN), or Repligen, following Repligen’s acquisition of the bioprocessing analytics portfolio of 908 Devices. From March 2023 through March 2025, he was our Chief Product Officer, and from February 2012 to March 2023, he was our Chief Technology Officer and Vice President of Research and Development. Prior to co-founding 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ: AAPL), leading investigations in future-gen health-technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific, Inc. (NYSE: TMO) and from 2005 until 2010 he was Senior Director… | Director | SELL | 15,030 | $106.0K | −14.8% | +18.6%hist |
| 4/8/2026 | Form 4 | MASS 10b5-1 | McCallion Kevin J. | SVP, Products and Production | SELL | 18,580 | $131.0K | −14.8% | −61.4%hist |
| 3/2/2026 | Form 4 | MASS 10b5-1 | McCallion Kevin J. | SVP, Products and Production | SELL | 7 | $49.00 | −30.6% | −61.4% |
| 3/2/2026 | Form 4 | MASS 10b5-1 | McCallion Kevin J. | SVP, Products and Production | SELL | 7 | $49.00 | −30.6% | −61.4% |
| 2/2/2026 | Form 4 | MASS | Knopp Kevin J. | President and CEO | SELL | 34,764 | $214.8K | −5.82% | −36.0% |
| 2/2/2026 | Form 4 | MASS | Griffith Joseph H. IV | Chief Financial Officer | SELL | 23,175 | $143.2K | −5.82% | −36.0% |
| 10/3/2025 | Form 4 | MASS 10b5-1 | Griffith Joseph H. IV | Chief Financial Officer | SELL | 4,292 | $38.8K | +43.9% | +31.5% |
| 10/2/2025 | Form 4 | MASS 10b5-1 | Griffith Joseph H. IV | Chief Financial Officer | SELL | 708 | $6.4K | +40.0% | +30.1% |
| 9/19/2025 | Form 4 | MASS 10b5-1 | Griffith Joseph H. IV | Chief Financial Officer | SELL | 5,000 | $35.4K | +25.6% | +17.9% |
| 6/18/2025 | Form 4 | MASS | Turner Michael S. | Chief Legal & Admin Officer | SELL | 1,373 | $10.3K | +22.7% | +25.8% |
| 6/17/2025 | Form 4 | MASS | Turner Michael S. | Chief Legal & Admin Officer | SELL | 7,148 | $53.7K | +18.1% | +19.6% |
| 6/16/2025 | Form 4 | MASS | Turner Michael S. | Chief Legal & Admin Officer | SELL | 16,082 | $120.8K | +16.3% | +17.8% |
| 6/4/2025 | Form 4 | MASS | Griffith Joseph H. IV | Chief Financial Officer | SELL | 6,940 | $49.1K | +13.9% | +11.0% |
| 5/15/2025 | Form 4 | MASS | Knopp Kevin J. | President and CEO | BUY | 15,000 | $66.6K | +56.0% | +30.4% |
| 5/14/2025 | Form 4 | MASS | Knopp Kevin J. | President and CEO | BUY | 15,000 | $64.8K | +49.8% | +48.0% |
| 5/14/2025 | Form 4 | MASS | Spoto MarkMark Spoto has served as a member of our board of directors since June 2012. Mr. Spoto is a Co-Founder and Managing Partner at Razor’s Edge Ventures, a multi-stage investment firm that invests in technology companies solving significant challenges in national security and high-growth commercial markets where he has been a partner since 2011. Prior to Razor’s Edge, Mr. Spoto was a partner at the national technology law firm of Cooley LLP. Mr. Spoto serves on the boards of directors of several private companies, including BlackVe, HawkEye 360, X-Bow Systems and mPower Technology. Mr. Spoto holds a B.S. in Aerospace Engineering from Boston University and a J.D. from Georgetown University Law Center. Our board… | Director | BUY | 3,000 | $12.8K | +49.8% | +48.0% |
| 5/14/2025 | Form 4 | MASS | Spoto MarkMark Spoto has served as a member of our board of directors since June 2012. Mr. Spoto is a Co-Founder and Managing Partner at Razor’s Edge Ventures, a multi-stage investment firm that invests in technology companies solving significant challenges in national security and high-growth commercial markets where he has been a partner since 2011. Prior to Razor’s Edge, Mr. Spoto was a partner at the national technology law firm of Cooley LLP. Mr. Spoto serves on the boards of directors of several private companies, including BlackVe, HawkEye 360, X-Bow Systems and mPower Technology. Mr. Spoto holds a B.S. in Aerospace Engineering from Boston University and a J.D. from Georgetown University Law Center. Our board… | Director | BUY | 7,000 | $30.1K | +49.8% | +48.0% |
| 2/3/2025 | Form 4 | MASS | Brown Christopher D.Dr. Brown has served as Vice President of R&D Analytics at Repligen Corporation (NASDAQ: RGEN), or Repligen, following Repligen’s acquisition of the bioprocessing analytics portfolio of 908 Devices. From March 2023 through March 2025, he was our Chief Product Officer, and from February 2012 to March 2023, he was our Chief Technology Officer and Vice President of Research and Development. Prior to co-founding 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ: AAPL), leading investigations in future-gen health-technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific, Inc. (NYSE: TMO) and from 2005 until 2010 he was Senior Director… | Chief Product Officer | SELL | 1,667 | $3.9K | −135.8% | −184.7% |
| 2/3/2025 | Form 4 | MASS | Brown Christopher D.Dr. Brown has served as Vice President of R&D Analytics at Repligen Corporation (NASDAQ: RGEN), or Repligen, following Repligen’s acquisition of the bioprocessing analytics portfolio of 908 Devices. From March 2023 through March 2025, he was our Chief Product Officer, and from February 2012 to March 2023, he was our Chief Technology Officer and Vice President of Research and Development. Prior to co-founding 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ: AAPL), leading investigations in future-gen health-technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific, Inc. (NYSE: TMO) and from 2005 until 2010 he was Senior Director… | Chief Product Officer | SELL | 3,641 | $8.5K | −135.8% | −184.7% |
| 2/3/2025 | Form 4 | MASS | Brown Christopher D.Dr. Brown has served as Vice President of R&D Analytics at Repligen Corporation (NASDAQ: RGEN), or Repligen, following Repligen’s acquisition of the bioprocessing analytics portfolio of 908 Devices. From March 2023 through March 2025, he was our Chief Product Officer, and from February 2012 to March 2023, he was our Chief Technology Officer and Vice President of Research and Development. Prior to co-founding 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ: AAPL), leading investigations in future-gen health-technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific, Inc. (NYSE: TMO) and from 2005 until 2010 he was Senior Director… | Chief Product Officer | SELL | 2,459 | $5.8K | −135.8% | −184.7% |
| 2/3/2025 | Form 4 | MASS | Knopp Kevin J. | President and CEO | SELL | 4,318 | $10.1K | −135.8% | −184.7% |
| 2/3/2025 | Form 4 | MASS | Knopp Kevin J. | President and CEO | SELL | 5,159 | $11.9K | −135.8% | −184.7% |
| 2/3/2025 | Form 4 | MASS | Knopp Kevin J. | President and CEO | SELL | 6,524 | $15.1K | −135.8% | −184.7% |
| 2/3/2025 | Form 4 | MASS | Turner Michael S. | Chief Legal & Admin Officer | SELL | 4,162 | $9.7K | −135.8% | −184.7% |
| 2/3/2025 | Form 4 | MASS | Turner Michael S. | Chief Legal & Admin Officer | SELL | 3,807 | $8.8K | −135.8% | −184.7% |
| 2/3/2025 | Form 4 | MASS | Turner Michael S. | Chief Legal & Admin Officer | SELL | 1,703 | $4.0K | −135.8% | −184.7% |
| 2/3/2025 | Form 4 | MASS | Griffith Joseph H. IV | Chief Financial Officer | SELL | 1,960 | $4.6K | −135.8% | −184.7% |
| 2/3/2025 | Form 4 | MASS | Griffith Joseph H. IV | Chief Financial Officer | SELL | 3,955 | $9.3K | −135.8% | −184.7% |
| 2/3/2025 | Form 4 | MASS | Griffith Joseph H. IV | Chief Financial Officer | SELL | 4,321 | $10.2K | −135.8% | −184.7% |
| 5/13/2024 | Form 4 | MASS | Knopp Kevin J. | President and CEO | BUY | 10,000 | $64.2K | −35.2% | −44.8% |
| 5/10/2024 | Form 4 | MASS | Knopp Kevin J. | President and CEO | BUY | 10,000 | $57.7K | −22.5% | −31.4% |
| 5/9/2024 | Form 4 | MASS | Knopp Kevin J. | President and CEO | BUY | 10,000 | $58.3K | −23.6% | −36.5% |
Chart shows split-adjusted close for the last three years, or the selected date range. Triangles mark open-market Form 4 purchases and sales in that window.